aluates Reports

$ 0.0

Automative

Global Circulating Tumor Cell Diagnostics Market Insights, Forecast to 2030

Published Date: September 2024

Report Code: QYRE-Othe-362

Global Circulating Tumor Cell Diagnostics Market Insights and Forecast to 2028

BUY CHAPTERS

Global Circulating Tumor Cell Diagnostics Market Insights, Forecast to 2030

Code: QYRE-Othe-362

Report

September 2024

Pages:126

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

Circulating Tumor Cell Diagnostics Market Size

The global Circulating Tumor Cell Diagnostics market is projected to grow from US$ 5449.1 million in 2024 to US$ 9239.7 million by 2030, at a Compound Annual Growth Rate (CAGR) of 9.2% during the forecast period.

Circulating Tumor Cell Diagnostics Market

Circulating tumor cells are significantly useful in determining the status of disease progression rate and projection of therapy needed for tumor eradication. Further development of various tumor markers that can be used along with companion diagnostics to diagnose or monitor various forms of cancer are expected to boost usage rates of CTC tests in the coming years.

Circulating tumor cell detection test possesses the ability to detect, quantify, and analyze tumor cells in the blood of cancer patients. It includes enrichment, detection and analysis of the detected circulating tumor cells. Circulating tumor cells tests are applicable in the characterization of tumor cells through biochemical marker analysis. CTC isolation, detection, and molecular characterization systems find investigational application in prostate, breast, colon, head, neck, skin, lung, and pancreatic cancer

Growing incidences oncology diseases and the introduction of novel biotechnological methods that enable the isolation and quantitation of circulating tumor cells. Furthermore, other factors like early disease diagnosis, cost savings on multiple treatments, drug safety, patient compliance, and optimization of therapies are attributive for rising demand for the preventive medicine, thus influencing the demand for CTC tests.

On course of the forecast period it is expected that over 150 companion diagnostic on-label combinations and a range of personalized therapeutic drugs under clinical trials and development pipelines based on companion diagnostics. The level of adoption of companion diagnostics is expected to significantly increase after these obtain complete FDA approval and are commercialized fully.

Market Analysis and Insights: Global Circulating Tumor Cell Diagnostics Market

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Covers:

This report presents an overview of global market for Circulating Tumor Cell Diagnostics market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.

This report researches the key producers of Circulating Tumor Cell Diagnostics, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Circulating Tumor Cell Diagnostics, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Circulating Tumor Cell Diagnostics revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global Circulating Tumor Cell Diagnostics market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Circulating Tumor Cell Diagnostics revenue, projected growth trends, production technology, application and end-user industry.

Market Segmentation

Scope of Circulating Tumor Cell Diagnostics Market Report

Report Metric	Details
Report Name	Circulating Tumor Cell Diagnostics Market
Accounted market size in 2024	US$ 5449.1 million
Forecasted market size in 2030	US$ 9239.7 million
CAGR	9.2
Base Year	2024
Forecasted years	2024 - 2030
Segment by Type	CTC Enrichment CTC Detection CTC Analysis
Segment by Application	Tumorigenesis research EMT biomarkers development Cancer stem cell research Others
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Janssen Diagnostics, Advanced Cell Diagnostics, Aviva Biosciences, Biocept Inc, Biofluidica Inc., CellTraffix Inc., Clearbridge BioMedics Pte Ltd, Epic Sciences Inc., Fluxion Biosciences Inc., ScreenCell, Silicon Biosystems, Sysmex Corporation, Greiner Bio-One GmbH, AdnaGen AG, Apocell Inc, Biocep Ltd, Canopus Bioscience Ltd, Creatv Microtech Inc, Ikonisys Inc, IV Diagnostics Inc, Miltenyi Biotech GmbH, Nanostring Technologies Inc, Rarecells Diagnostics., Vitatex Inc
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Circulating Tumor Cell Diagnostics in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Circulating Tumor Cell Diagnostics companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, revenue for each segment.
Chapter 8: China by Type, and by Application, revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Circulating Tumor Cell Diagnostics revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions

FAQ for this report

How fast is Circulating Tumor Cell Diagnostics Market growing?

Ans: The Circulating Tumor Cell Diagnostics Market witnessing a CAGR of 9.2 during the forecast period 2024-2030.

What is the Circulating Tumor Cell Diagnostics Market size in 2030?

Ans: The Circulating Tumor Cell Diagnostics Market size in 2030 will be US$ 9239.7 million.

Who are the main players in the Circulating Tumor Cell Diagnostics Market report?

Ans: The main players in the Circulating Tumor Cell Diagnostics Market are Janssen Diagnostics, Advanced Cell Diagnostics, Aviva Biosciences, Biocept Inc, Biofluidica Inc., CellTraffix Inc., Clearbridge BioMedics Pte Ltd, Epic Sciences Inc., Fluxion Biosciences Inc., ScreenCell, Silicon Biosystems, Sysmex Corporation, Greiner Bio-One GmbH, AdnaGen AG, Apocell Inc, Biocep Ltd, Canopus Bioscience Ltd, Creatv Microtech Inc, Ikonisys Inc, IV Diagnostics Inc, Miltenyi Biotech GmbH, Nanostring Technologies Inc, Rarecells Diagnostics., Vitatex Inc

What are the Application segmentation covered in the Circulating Tumor Cell Diagnostics Market report?

Ans: The Applications covered in the Circulating Tumor Cell Diagnostics Market report are Tumorigenesis research, EMT biomarkers development, Cancer stem cell research, Others

What are the Type segmentation covered in the Circulating Tumor Cell Diagnostics Market report?

Ans: The Types covered in the Circulating Tumor Cell Diagnostics Market report are CTC Enrichment, CTC Detection, CTC Analysis

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Circulating Tumor Cell Diagnostics Market Size Growth Rate by Type, 2019 VS 2023 VS 2030

1.2.2 CTC Enrichment

1.2.3 CTC Detection

1.2.4 CTC Analysis

1.3 Market by Application

1.3.1 Global Circulating Tumor Cell Diagnostics Market Size Growth Rate by Application, 2019 VS 2023 VS 2030

1.3.2 Tumorigenesis research

1.3.3 EMT biomarkers development

1.3.4 Cancer stem cell research

1.3.5 Others

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Circulating Tumor Cell Diagnostics Market Perspective (2019-2030)

2.2 Global Circulating Tumor Cell Diagnostics Growth Trends by Region

2.2.1 Circulating Tumor Cell Diagnostics Market Size by Region: 2019 VS 2023 VS 2030

2.2.2 Circulating Tumor Cell Diagnostics Historic Market Size by Region (2019-2024)

2.2.3 Circulating Tumor Cell Diagnostics Forecasted Market Size by Region (2025-2030)

2.3 Circulating Tumor Cell Diagnostics Market Dynamics

2.3.1 Circulating Tumor Cell Diagnostics Industry Trends

2.3.2 Circulating Tumor Cell Diagnostics Market Drivers

2.3.3 Circulating Tumor Cell Diagnostics Market Challenges

2.3.4 Circulating Tumor Cell Diagnostics Market Restraints

3 Competition Landscape by Key Players

3.1 Global Revenue Circulating Tumor Cell Diagnostics by Players

3.1.1 Global Circulating Tumor Cell Diagnostics Revenue by Players (2019-2024)

3.1.2 Global Circulating Tumor Cell Diagnostics Revenue Market Share by Players (2019-2024)

3.2 Global Circulating Tumor Cell Diagnostics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players of Circulating Tumor Cell Diagnostics, Ranking by Revenue, 2022 VS 2023 VS 2024

3.4 Global Circulating Tumor Cell Diagnostics Market Concentration Ratio

3.4.1 Global Circulating Tumor Cell Diagnostics Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Circulating Tumor Cell Diagnostics Revenue in 2023

3.5 Global Key Players of Circulating Tumor Cell Diagnostics Head office and Area Served

3.6 Global Key Players of Circulating Tumor Cell Diagnostics, Product and Application

3.7 Global Key Players of Circulating Tumor Cell Diagnostics, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 Circulating Tumor Cell Diagnostics Breakdown Data by Type

4.1 Global Circulating Tumor Cell Diagnostics Historic Market Size by Type (2019-2024)

4.2 Global Circulating Tumor Cell Diagnostics Forecasted Market Size by Type (2025-2030)

5 Circulating Tumor Cell Diagnostics Breakdown Data by Application

5.1 Global Circulating Tumor Cell Diagnostics Historic Market Size by Application (2019-2024)

5.2 Global Circulating Tumor Cell Diagnostics Forecasted Market Size by Application (2025-2030)

6 North America

6.1 North America Circulating Tumor Cell Diagnostics Market Size (2019-2030)

6.2 North America Circulating Tumor Cell Diagnostics Market Size by Type

6.2.1 North America Circulating Tumor Cell Diagnostics Market Size by Type (2019-2024)

6.2.2 North America Circulating Tumor Cell Diagnostics Market Size by Type (2025-2030)

6.2.3 North America Circulating Tumor Cell Diagnostics Market Share by Type (2019-2030)

6.3 North America Circulating Tumor Cell Diagnostics Market Size by Application

6.3.1 North America Circulating Tumor Cell Diagnostics Market Size by Application (2019-2024)

6.3.2 North America Circulating Tumor Cell Diagnostics Market Size by Application (2025-2030)

6.3.3 North America Circulating Tumor Cell Diagnostics Market Share by Application (2019-2030)

6.4 North America Circulating Tumor Cell Diagnostics Market Size by Country

6.4.1 North America Circulating Tumor Cell Diagnostics Market Size by Country: 2019 VS 2023 VS 2030

6.4.2 North America Circulating Tumor Cell Diagnostics Market Size by Country (2019-2024)

6.4.3 North America Circulating Tumor Cell Diagnostics Market Size by Country (2025-2030)

6.4.4 U.S.

6.4.5 Canada

7 Europe

7.1 Europe Circulating Tumor Cell Diagnostics Market Size (2019-2030)

7.2 Europe Circulating Tumor Cell Diagnostics Market Size by Type

7.2.1 Europe Circulating Tumor Cell Diagnostics Market Size by Type (2019-2024)

7.2.2 Europe Circulating Tumor Cell Diagnostics Market Size by Type (2025-2030)

7.2.3 Europe Circulating Tumor Cell Diagnostics Market Share by Type (2019-2030)

7.3 Europe Circulating Tumor Cell Diagnostics Market Size by Application

7.3.1 Europe Circulating Tumor Cell Diagnostics Market Size by Application (2019-2024)

7.3.2 Europe Circulating Tumor Cell Diagnostics Market Size by Application (2025-2030)

7.3.3 Europe Circulating Tumor Cell Diagnostics Market Share by Application (2019-2030)

7.4 Europe Circulating Tumor Cell Diagnostics Market Size by Country

7.4.1 Europe Circulating Tumor Cell Diagnostics Market Size by Country: 2019 VS 2023 VS 2030

7.4.2 Europe Circulating Tumor Cell Diagnostics Market Size by Country (2019-2024)

7.4.3 Europe Circulating Tumor Cell Diagnostics Market Size by Country (2025-2030)

7.4.3 Germany

7.4.4 France

7.4.5 U.K.

7.4.6 Italy

7.4.7 Russia

7.4.8 Nordic Countries

8 China

8.1 China Circulating Tumor Cell Diagnostics Market Size (2019-2030)

8.2 China Circulating Tumor Cell Diagnostics Market Size by Type

8.2.1 China Circulating Tumor Cell Diagnostics Market Size by Type (2019-2024)

8.2.2 China Circulating Tumor Cell Diagnostics Market Size by Type (2025-2030)

8.2.3 China Circulating Tumor Cell Diagnostics Market Share by Type (2019-2030)

8.3 China Circulating Tumor Cell Diagnostics Market Size by Application

8.3.1 China Circulating Tumor Cell Diagnostics Market Size by Application (2019-2024)

8.3.2 China Circulating Tumor Cell Diagnostics Market Size by Application (2025-2030)

8.3.3 China Circulating Tumor Cell Diagnostics Market Share by Application (2019-2030)

9 Asia (excluding China)

9.1 Asia Circulating Tumor Cell Diagnostics Market Size (2019-2030)

9.2 Asia Circulating Tumor Cell Diagnostics Market Size by Type

9.2.1 Asia Circulating Tumor Cell Diagnostics Market Size by Type (2019-2024)

9.2.2 Asia Circulating Tumor Cell Diagnostics Market Size by Type (2025-2030)

9.2.3 Asia Circulating Tumor Cell Diagnostics Market Share by Type (2019-2030)

9.3 Asia Circulating Tumor Cell Diagnostics Market Size by Application

9.3.1 Asia Circulating Tumor Cell Diagnostics Market Size by Application (2019-2024)

9.3.2 Asia Circulating Tumor Cell Diagnostics Market Size by Application (2025-2030)

9.3.3 Asia Circulating Tumor Cell Diagnostics Market Share by Application (2019-2030)

9.4 Asia Circulating Tumor Cell Diagnostics Market Size by Region

9.4.1 Asia Circulating Tumor Cell Diagnostics Market Size by Region: 2019 VS 2023 VS 2030

9.4.2 Asia Circulating Tumor Cell Diagnostics Market Size by Region (2019-2024)

9.4.3 Asia Circulating Tumor Cell Diagnostics Market Size by Region (2025-2030)

9.4.4 Japan

9.4.5 South Korea

9.4.6 China Taiwan

9.4.7 Southeast Asia

9.4.8 India

9.4.9 Australia

10 Middle East, Africa, and Latin America

10.1 Middle East, Africa, and Latin America Circulating Tumor Cell Diagnostics Market Size (2019-2030)

10.2 Middle East, Africa, and Latin America Circulating Tumor Cell Diagnostics Market Size by Type

10.2.1 Middle East, Africa, and Latin America Circulating Tumor Cell Diagnostics Market Size by Type (2019-2024)

10.2.2 Middle East, Africa, and Latin America Circulating Tumor Cell Diagnostics Market Size by Type (2025-2030)

10.2.3 Middle East, Africa, and Latin America Circulating Tumor Cell Diagnostics Market Share by Type (2019-2030)

10.3 Middle East, Africa, and Latin America Circulating Tumor Cell Diagnostics Market Size by Application

10.3.1 Middle East, Africa, and Latin America Circulating Tumor Cell Diagnostics Market Size by Application (2019-2024)

10.3.2 Middle East, Africa, and Latin America Circulating Tumor Cell Diagnostics Market Size by Application (2025-2030)

10.3.3 Middle East, Africa, and Latin America Circulating Tumor Cell Diagnostics Market Share by Application (2019-2030)

10.4 Middle East, Africa, and Latin America Circulating Tumor Cell Diagnostics Market Size by Country

10.4.1 Middle East, Africa, and Latin America Circulating Tumor Cell Diagnostics Market Size by Country: 2019 VS 2023 VS 2030

10.4.2 Middle East, Africa, and Latin America Circulating Tumor Cell Diagnostics Market Size by Country (2019-2024)

10.4.3 Middle East, Africa, and Latin America Circulating Tumor Cell Diagnostics Market Size by Country (2025-2030)

10.4.4 Brazil

10.4.5 Mexico

10.4.6 Turkey

10.4.7 Saudi Arabia

10.4.8 Israel

10.4.9 GCC Countries

11 Key Players Profiles

11.1 Janssen Diagnostics

11.1.1 Janssen Diagnostics Company Details

11.1.2 Janssen Diagnostics Business Overview

11.1.3 Janssen Diagnostics Circulating Tumor Cell Diagnostics Introduction

11.1.4 Janssen Diagnostics Revenue in Circulating Tumor Cell Diagnostics Business (2019-2024)

11.1.5 Janssen Diagnostics Recent Developments

11.2 Advanced Cell Diagnostics

11.2.1 Advanced Cell Diagnostics Company Details

11.2.2 Advanced Cell Diagnostics Business Overview

11.2.3 Advanced Cell Diagnostics Circulating Tumor Cell Diagnostics Introduction

11.2.4 Advanced Cell Diagnostics Revenue in Circulating Tumor Cell Diagnostics Business (2019-2024)

11.2.5 Advanced Cell Diagnostics Recent Developments

11.3 Aviva Biosciences

11.3.1 Aviva Biosciences Company Details

11.3.2 Aviva Biosciences Business Overview

11.3.3 Aviva Biosciences Circulating Tumor Cell Diagnostics Introduction

11.3.4 Aviva Biosciences Revenue in Circulating Tumor Cell Diagnostics Business (2019-2024)

11.3.5 Aviva Biosciences Recent Developments

11.4 Biocept Inc

11.4.1 Biocept Inc Company Details

11.4.2 Biocept Inc Business Overview

11.4.3 Biocept Inc Circulating Tumor Cell Diagnostics Introduction

11.4.4 Biocept Inc Revenue in Circulating Tumor Cell Diagnostics Business (2019-2024)

11.4.5 Biocept Inc Recent Developments

11.5 Biofluidica Inc.

11.5.1 Biofluidica Inc. Company Details

11.5.2 Biofluidica Inc. Business Overview

11.5.3 Biofluidica Inc. Circulating Tumor Cell Diagnostics Introduction

11.5.4 Biofluidica Inc. Revenue in Circulating Tumor Cell Diagnostics Business (2019-2024)

11.5.5 Biofluidica Inc. Recent Developments

11.6 CellTraffix Inc.

11.6.1 CellTraffix Inc. Company Details

11.6.2 CellTraffix Inc. Business Overview

11.6.3 CellTraffix Inc. Circulating Tumor Cell Diagnostics Introduction

11.6.4 CellTraffix Inc. Revenue in Circulating Tumor Cell Diagnostics Business (2019-2024)

11.6.5 CellTraffix Inc. Recent Developments

11.7 Clearbridge BioMedics Pte Ltd

11.7.1 Clearbridge BioMedics Pte Ltd Company Details

11.7.2 Clearbridge BioMedics Pte Ltd Business Overview

11.7.3 Clearbridge BioMedics Pte Ltd Circulating Tumor Cell Diagnostics Introduction

11.7.4 Clearbridge BioMedics Pte Ltd Revenue in Circulating Tumor Cell Diagnostics Business (2019-2024)

11.7.5 Clearbridge BioMedics Pte Ltd Recent Developments

11.8 Epic Sciences Inc.

11.8.1 Epic Sciences Inc. Company Details

11.8.2 Epic Sciences Inc. Business Overview

11.8.3 Epic Sciences Inc. Circulating Tumor Cell Diagnostics Introduction

11.8.4 Epic Sciences Inc. Revenue in Circulating Tumor Cell Diagnostics Business (2019-2024)

11.8.5 Epic Sciences Inc. Recent Developments

11.9 Fluxion Biosciences Inc.

11.9.1 Fluxion Biosciences Inc. Company Details

11.9.2 Fluxion Biosciences Inc. Business Overview

11.9.3 Fluxion Biosciences Inc. Circulating Tumor Cell Diagnostics Introduction

11.9.4 Fluxion Biosciences Inc. Revenue in Circulating Tumor Cell Diagnostics Business (2019-2024)

11.9.5 Fluxion Biosciences Inc. Recent Developments

11.10 ScreenCell

11.10.1 ScreenCell Company Details

11.10.2 ScreenCell Business Overview

11.10.3 ScreenCell Circulating Tumor Cell Diagnostics Introduction

11.10.4 ScreenCell Revenue in Circulating Tumor Cell Diagnostics Business (2019-2024)

11.10.5 ScreenCell Recent Developments

11.11 Silicon Biosystems

11.11.1 Silicon Biosystems Company Details

11.11.2 Silicon Biosystems Business Overview

11.11.3 Silicon Biosystems Circulating Tumor Cell Diagnostics Introduction

11.11.4 Silicon Biosystems Revenue in Circulating Tumor Cell Diagnostics Business (2019-2024)

11.11.5 Silicon Biosystems Recent Developments

11.12 Sysmex Corporation

11.12.1 Sysmex Corporation Company Details

11.12.2 Sysmex Corporation Business Overview

11.12.3 Sysmex Corporation Circulating Tumor Cell Diagnostics Introduction

11.12.4 Sysmex Corporation Revenue in Circulating Tumor Cell Diagnostics Business (2019-2024)

11.12.5 Sysmex Corporation Recent Developments

11.13 Greiner Bio-One GmbH

11.13.1 Greiner Bio-One GmbH Company Details

11.13.2 Greiner Bio-One GmbH Business Overview

11.13.3 Greiner Bio-One GmbH Circulating Tumor Cell Diagnostics Introduction

11.13.4 Greiner Bio-One GmbH Revenue in Circulating Tumor Cell Diagnostics Business (2019-2024)

11.13.5 Greiner Bio-One GmbH Recent Developments

11.14 AdnaGen AG

11.14.1 AdnaGen AG Company Details

11.14.2 AdnaGen AG Business Overview

11.14.3 AdnaGen AG Circulating Tumor Cell Diagnostics Introduction

11.14.4 AdnaGen AG Revenue in Circulating Tumor Cell Diagnostics Business (2019-2024)

11.14.5 AdnaGen AG Recent Developments

11.15 Apocell Inc

11.15.1 Apocell Inc Company Details

11.15.2 Apocell Inc Business Overview

11.15.3 Apocell Inc Circulating Tumor Cell Diagnostics Introduction

11.15.4 Apocell Inc Revenue in Circulating Tumor Cell Diagnostics Business (2019-2024)

11.15.5 Apocell Inc Recent Developments

11.16 Biocep Ltd

11.16.1 Biocep Ltd Company Details

11.16.2 Biocep Ltd Business Overview

11.16.3 Biocep Ltd Circulating Tumor Cell Diagnostics Introduction

11.16.4 Biocep Ltd Revenue in Circulating Tumor Cell Diagnostics Business (2019-2024)

11.16.5 Biocep Ltd Recent Developments

11.17 Canopus Bioscience Ltd

11.17.1 Canopus Bioscience Ltd Company Details

11.17.2 Canopus Bioscience Ltd Business Overview

11.17.3 Canopus Bioscience Ltd Circulating Tumor Cell Diagnostics Introduction

11.17.4 Canopus Bioscience Ltd Revenue in Circulating Tumor Cell Diagnostics Business (2019-2024)

11.17.5 Canopus Bioscience Ltd Recent Developments

11.18 Creatv Microtech Inc

11.18.1 Creatv Microtech Inc Company Details

11.18.2 Creatv Microtech Inc Business Overview

11.18.3 Creatv Microtech Inc Circulating Tumor Cell Diagnostics Introduction

11.18.4 Creatv Microtech Inc Revenue in Circulating Tumor Cell Diagnostics Business (2019-2024)

11.18.5 Creatv Microtech Inc Recent Developments

11.19 Ikonisys Inc

11.19.1 Ikonisys Inc Company Details

11.19.2 Ikonisys Inc Business Overview

11.19.3 Ikonisys Inc Circulating Tumor Cell Diagnostics Introduction

11.19.4 Ikonisys Inc Revenue in Circulating Tumor Cell Diagnostics Business (2019-2024)

11.19.5 Ikonisys Inc Recent Developments

11.20 IV Diagnostics Inc

11.20.1 IV Diagnostics Inc Company Details

11.20.2 IV Diagnostics Inc Business Overview

11.20.3 IV Diagnostics Inc Circulating Tumor Cell Diagnostics Introduction

11.20.4 IV Diagnostics Inc Revenue in Circulating Tumor Cell Diagnostics Business (2019-2024)

11.20.5 IV Diagnostics Inc Recent Developments

11.21 Miltenyi Biotech GmbH

11.21.1 Miltenyi Biotech GmbH Company Details

11.21.2 Miltenyi Biotech GmbH Business Overview

11.21.3 Miltenyi Biotech GmbH Circulating Tumor Cell Diagnostics Introduction

11.21.4 Miltenyi Biotech GmbH Revenue in Circulating Tumor Cell Diagnostics Business (2019-2024)

11.21.5 Miltenyi Biotech GmbH Recent Developments

11.22 Nanostring Technologies Inc

11.22.1 Nanostring Technologies Inc Company Details

11.22.2 Nanostring Technologies Inc Business Overview

11.22.3 Nanostring Technologies Inc Circulating Tumor Cell Diagnostics Introduction

11.22.4 Nanostring Technologies Inc Revenue in Circulating Tumor Cell Diagnostics Business (2019-2024)

11.22.5 Nanostring Technologies Inc Recent Developments

11.23 Rarecells Diagnostics.

11.23.1 Rarecells Diagnostics. Company Details

11.23.2 Rarecells Diagnostics. Business Overview

11.23.3 Rarecells Diagnostics. Circulating Tumor Cell Diagnostics Introduction

11.23.4 Rarecells Diagnostics. Revenue in Circulating Tumor Cell Diagnostics Business (2019-2024)

11.23.5 Rarecells Diagnostics. Recent Developments

11.24 Vitatex Inc

11.24.1 Vitatex Inc Company Details

11.24.2 Vitatex Inc Business Overview

11.24.3 Vitatex Inc Circulating Tumor Cell Diagnostics Introduction

11.24.4 Vitatex Inc Revenue in Circulating Tumor Cell Diagnostics Business (2019-2024)

11.24.5 Vitatex Inc Recent Developments

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Disclaimer

13.3 Author Details

List of Tables

Table 1. Global Circulating Tumor Cell Diagnostics Market Size Growth Rate by Type (US$ Million), 2019 VS 2023 VS 2030

Table 2. Key Players of CTC Enrichment

Table 3. Key Players of CTC Detection

Table 4. Key Players of CTC Analysis

Table 5. Global Circulating Tumor Cell Diagnostics Market Size Growth Rate by Application (US$ Million), 2019 VS 2023 VS 2030

Table 6. Global Circulating Tumor Cell Diagnostics Market Size Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030

Table 7. Global Circulating Tumor Cell Diagnostics Market Size by Region (2019-2024) & (US$ Million)

Table 8. Global Circulating Tumor Cell Diagnostics Market Share by Region (2019-2024)

Table 9. Global Circulating Tumor Cell Diagnostics Forecasted Market Size by Region (2025-2030) & (US$ Million)

Table 10. Global Circulating Tumor Cell Diagnostics Market Share by Region (2025-2030)

Table 11. Circulating Tumor Cell Diagnostics Market Trends

Table 12. Circulating Tumor Cell Diagnostics Market Drivers

Table 13. Circulating Tumor Cell Diagnostics Market Challenges

Table 14. Circulating Tumor Cell Diagnostics Market Restraints

Table 15. Global Circulating Tumor Cell Diagnostics Revenue by Players (2019-2024) & (US$ Million)

Table 16. Global Circulating Tumor Cell Diagnostics Revenue Share by Players (2019-2024)

Table 17. Global Top Circulating Tumor Cell Diagnostics by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Circulating Tumor Cell Diagnostics as of 2023)

Table 18. Global Circulating Tumor Cell Diagnostics Industry Ranking 2022 VS 2023 VS 2024

Table 19. Global 5 Largest Players Market Share by Circulating Tumor Cell Diagnostics Revenue (CR5 and HHI) & (2019-2024)

Table 20. Global Key Players of Circulating Tumor Cell Diagnostics, Headquarters and Area Served

Table 21. Global Key Players of Circulating Tumor Cell Diagnostics, Product and Application

Table 22. Global Key Players of Circulating Tumor Cell Diagnostics, Product and Application

Table 23. Mergers & Acquisitions, Expansion Plans

Table 24. Global Circulating Tumor Cell Diagnostics Market Size by Type (2019-2024) & (US$ Million)

Table 25. Global Circulating Tumor Cell Diagnostics Revenue Market Share by Type (2019-2024)

Table 26. Global Circulating Tumor Cell Diagnostics Forecasted Market Size by Type (2025-2030) & (US$ Million)

Table 27. Global Circulating Tumor Cell Diagnostics Revenue Market Share by Type (2025-2030)

Table 28. Global Circulating Tumor Cell Diagnostics Market Size by Application (2019-2024) & (US$ Million)

Table 29. Global Circulating Tumor Cell Diagnostics Revenue Share by Application (2019-2024)

Table 30. Global Circulating Tumor Cell Diagnostics Forecasted Market Size by Application (2025-2030) & (US$ Million)

Table 31. Global Circulating Tumor Cell Diagnostics Revenue Share by Application (2025-2030)

Table 32. North America Circulating Tumor Cell Diagnostics Market Size by Type (2019-2024) & (US$ Million)

Table 33. North America Circulating Tumor Cell Diagnostics Market Size by Type (2025-2030) & (US$ Million)

Table 34. North America Circulating Tumor Cell Diagnostics Market Size by Application (2019-2024) & (US$ Million)

Table 35. North America Circulating Tumor Cell Diagnostics Market Size by Application (2025-2030) & (US$ Million)

Table 36. North America Circulating Tumor Cell Diagnostics Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030

Table 37. North America Circulating Tumor Cell Diagnostics Market Size by Country (2019-2024) & (US$ Million)

Table 38. North America Circulating Tumor Cell Diagnostics Market Size by Country (2025-2030) & (US$ Million)

Table 39. Europe Circulating Tumor Cell Diagnostics Market Size by Type (2019-2024) & (US$ Million)

Table 40. Europe Circulating Tumor Cell Diagnostics Market Size by Type (2025-2030) & (US$ Million)

Table 41. Europe Circulating Tumor Cell Diagnostics Market Size by Application (2019-2024) & (US$ Million)

Table 42. Europe Circulating Tumor Cell Diagnostics Market Size by Application (2025-2030) & (US$ Million)

Table 43. Europe Circulating Tumor Cell Diagnostics Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030

Table 44. Europe Circulating Tumor Cell Diagnostics Market Size by Country (2019-2024) & (US$ Million)

Table 45. Europe Circulating Tumor Cell Diagnostics Market Size by Country (2025-2030) & (US$ Million)

Table 46. China Circulating Tumor Cell Diagnostics Market Size by Type (2019-2024) & (US$ Million)

Table 47. China Circulating Tumor Cell Diagnostics Market Size by Type (2025-2030) & (US$ Million)

Table 48. China Circulating Tumor Cell Diagnostics Market Size by Application (2019-2024) & (US$ Million)

Table 49. China Circulating Tumor Cell Diagnostics Market Size by Application (2025-2030) & (US$ Million)

Table 50. Asia Circulating Tumor Cell Diagnostics Market Size by Type (2019-2024) & (US$ Million)

Table 51. Asia Circulating Tumor Cell Diagnostics Market Size by Type (2025-2030) & (US$ Million)

Table 52. Asia Circulating Tumor Cell Diagnostics Market Size by Application (2019-2024) & (US$ Million)

Table 53. Asia Circulating Tumor Cell Diagnostics Market Size by Application (2025-2030) & (US$ Million)

Table 54. Asia Circulating Tumor Cell Diagnostics Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030

Table 55. Asia Circulating Tumor Cell Diagnostics Market Size by Region (2019-2024) & (US$ Million)

Table 56. Asia Circulating Tumor Cell Diagnostics Market Size by Region (2025-2030) & (US$ Million)

Table 57. Middle East, Africa, and Latin America Circulating Tumor Cell Diagnostics Market Size by Type (2019-2024) & (US$ Million)

Table 58. Middle East, Africa, and Latin America Circulating Tumor Cell Diagnostics Market Size by Type (2025-2030) & (US$ Million)

Table 59. Middle East, Africa, and Latin America Circulating Tumor Cell Diagnostics Market Size by Application (2019-2024) & (US$ Million)

Table 60. Middle East, Africa, and Latin America Circulating Tumor Cell Diagnostics Market Size by Application (2025-2030) & (US$ Million)

Table 61. Middle East, Africa, and Latin America Circulating Tumor Cell Diagnostics Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030

Table 62. Middle East, Africa, and Latin America Circulating Tumor Cell Diagnostics Market Size by Country (2019-2024) & (US$ Million)

Table 63. Middle East, Africa, and Latin America Circulating Tumor Cell Diagnostics Market Size by Country (2025-2030) & (US$ Million)

Table 64. Janssen Diagnostics Company Details

Table 65. Janssen Diagnostics Business Overview

Table 66. Janssen Diagnostics Circulating Tumor Cell Diagnostics Product

Table 67. Janssen Diagnostics Revenue in Circulating Tumor Cell Diagnostics Business (2019-2024) & (US$ Million)

Table 68. Janssen Diagnostics Recent Developments

Table 69. Advanced Cell Diagnostics Company Details

Table 70. Advanced Cell Diagnostics Business Overview

Table 71. Advanced Cell Diagnostics Circulating Tumor Cell Diagnostics Product

Table 72. Advanced Cell Diagnostics Revenue in Circulating Tumor Cell Diagnostics Business (2019-2024) & (US$ Million)

Table 73. Advanced Cell Diagnostics Recent Developments

Table 74. Aviva Biosciences Company Details

Table 75. Aviva Biosciences Business Overview

Table 76. Aviva Biosciences Circulating Tumor Cell Diagnostics Product

Table 77. Aviva Biosciences Revenue in Circulating Tumor Cell Diagnostics Business (2019-2024) & (US$ Million)

Table 78. Aviva Biosciences Recent Developments

Table 79. Biocept Inc Company Details

Table 80. Biocept Inc Business Overview

Table 81. Biocept Inc Circulating Tumor Cell Diagnostics Product

Table 82. Biocept Inc Revenue in Circulating Tumor Cell Diagnostics Business (2019-2024) & (US$ Million)

Table 83. Biocept Inc Recent Developments

Table 84. Biofluidica Inc. Company Details

Table 85. Biofluidica Inc. Business Overview

Table 86. Biofluidica Inc. Circulating Tumor Cell Diagnostics Product

Table 87. Biofluidica Inc. Revenue in Circulating Tumor Cell Diagnostics Business (2019-2024) & (US$ Million)

Table 88. Biofluidica Inc. Recent Developments

Table 89. CellTraffix Inc. Company Details

Table 90. CellTraffix Inc. Business Overview

Table 91. CellTraffix Inc. Circulating Tumor Cell Diagnostics Product

Table 92. CellTraffix Inc. Revenue in Circulating Tumor Cell Diagnostics Business (2019-2024) & (US$ Million)

Table 93. CellTraffix Inc. Recent Developments

Table 94. Clearbridge BioMedics Pte Ltd Company Details

Table 95. Clearbridge BioMedics Pte Ltd Business Overview

Table 96. Clearbridge BioMedics Pte Ltd Circulating Tumor Cell Diagnostics Product

Table 97. Clearbridge BioMedics Pte Ltd Revenue in Circulating Tumor Cell Diagnostics Business (2019-2024) & (US$ Million)

Table 98. Clearbridge BioMedics Pte Ltd Recent Developments

Table 99. Epic Sciences Inc. Company Details

Table 100. Epic Sciences Inc. Business Overview

Table 101. Epic Sciences Inc. Circulating Tumor Cell Diagnostics Product

Table 102. Epic Sciences Inc. Revenue in Circulating Tumor Cell Diagnostics Business (2019-2024) & (US$ Million)

Table 103. Epic Sciences Inc. Recent Developments

Table 104. Fluxion Biosciences Inc. Company Details

Table 105. Fluxion Biosciences Inc. Business Overview

Table 106. Fluxion Biosciences Inc. Circulating Tumor Cell Diagnostics Product

Table 107. Fluxion Biosciences Inc. Revenue in Circulating Tumor Cell Diagnostics Business (2019-2024) & (US$ Million)

Table 108. Fluxion Biosciences Inc. Recent Developments

Table 109. ScreenCell Company Details

Table 110. ScreenCell Business Overview

Table 111. ScreenCell Circulating Tumor Cell Diagnostics Product

Table 112. ScreenCell Revenue in Circulating Tumor Cell Diagnostics Business (2019-2024) & (US$ Million)

Table 113. ScreenCell Recent Developments

Table 114. Silicon Biosystems Company Details

Table 115. Silicon Biosystems Business Overview

Table 116. Silicon Biosystems Circulating Tumor Cell Diagnostics Product

Table 117. Silicon Biosystems Revenue in Circulating Tumor Cell Diagnostics Business (2019-2024) & (US$ Million)

Table 118. Silicon Biosystems Recent Developments

Table 119. Sysmex Corporation Company Details

Table 120. Sysmex Corporation Business Overview

Table 121. Sysmex Corporation Circulating Tumor Cell Diagnostics Product

Table 122. Sysmex Corporation Revenue in Circulating Tumor Cell Diagnostics Business (2019-2024) & (US$ Million)

Table 123. Sysmex Corporation Recent Developments

Table 124. Greiner Bio-One GmbH Company Details

Table 125. Greiner Bio-One GmbH Business Overview

Table 126. Greiner Bio-One GmbH Circulating Tumor Cell Diagnostics Product

Table 127. Greiner Bio-One GmbH Revenue in Circulating Tumor Cell Diagnostics Business (2019-2024) & (US$ Million)

Table 128. Greiner Bio-One GmbH Recent Developments

Table 129. AdnaGen AG Company Details

Table 130. AdnaGen AG Business Overview

Table 131. AdnaGen AG Circulating Tumor Cell Diagnostics Product

Table 132. AdnaGen AG Revenue in Circulating Tumor Cell Diagnostics Business (2019-2024) & (US$ Million)

Table 133. AdnaGen AG Recent Developments

Table 134. Apocell Inc Company Details

Table 135. Apocell Inc Business Overview

Table 136. Apocell Inc Circulating Tumor Cell Diagnostics Product

Table 137. Apocell Inc Revenue in Circulating Tumor Cell Diagnostics Business (2019-2024) & (US$ Million)

Table 138. Apocell Inc Recent Developments

Table 139. Biocep Ltd Company Details

Table 140. Biocep Ltd Business Overview

Table 141. Biocep Ltd Circulating Tumor Cell Diagnostics Product

Table 142. Biocep Ltd Revenue in Circulating Tumor Cell Diagnostics Business (2019-2024) & (US$ Million)

Table 143. Biocep Ltd Recent Developments

Table 144. Canopus Bioscience Ltd Company Details

Table 145. Canopus Bioscience Ltd Business Overview

Table 146. Canopus Bioscience Ltd Circulating Tumor Cell Diagnostics Product

Table 147. Canopus Bioscience Ltd Revenue in Circulating Tumor Cell Diagnostics Business (2019-2024) & (US$ Million)

Table 148. Canopus Bioscience Ltd Recent Developments

Table 149. Creatv Microtech Inc Company Details

Table 150. Creatv Microtech Inc Business Overview

Table 151. Creatv Microtech Inc Circulating Tumor Cell Diagnostics Product

Table 152. Creatv Microtech Inc Revenue in Circulating Tumor Cell Diagnostics Business (2019-2024) & (US$ Million)

Table 153. Creatv Microtech Inc Recent Developments

Table 154. Ikonisys Inc Company Details

Table 155. Ikonisys Inc Business Overview

Table 156. Ikonisys Inc Circulating Tumor Cell Diagnostics Product

Table 157. Ikonisys Inc Revenue in Circulating Tumor Cell Diagnostics Business (2019-2024) & (US$ Million)

Table 158. Ikonisys Inc Recent Developments

Table 159. IV Diagnostics Inc Company Details

Table 160. IV Diagnostics Inc Business Overview

Table 161. IV Diagnostics Inc Circulating Tumor Cell Diagnostics Product

Table 162. IV Diagnostics Inc Revenue in Circulating Tumor Cell Diagnostics Business (2019-2024) & (US$ Million)

Table 163. IV Diagnostics Inc Recent Developments

Table 164. Miltenyi Biotech GmbH Company Details

Table 165. Miltenyi Biotech GmbH Business Overview

Table 166. Miltenyi Biotech GmbH Circulating Tumor Cell Diagnostics Product

Table 167. Miltenyi Biotech GmbH Revenue in Circulating Tumor Cell Diagnostics Business (2019-2024) & (US$ Million)

Table 168. Miltenyi Biotech GmbH Recent Developments

Table 169. Nanostring Technologies Inc Company Details

Table 170. Nanostring Technologies Inc Business Overview

Table 171. Nanostring Technologies Inc Circulating Tumor Cell Diagnostics Product

Table 172. Nanostring Technologies Inc Revenue in Circulating Tumor Cell Diagnostics Business (2019-2024) & (US$ Million)

Table 173. Nanostring Technologies Inc Recent Developments

Table 174. Rarecells Diagnostics. Company Details

Table 175. Rarecells Diagnostics. Business Overview

Table 176. Rarecells Diagnostics. Circulating Tumor Cell Diagnostics Product

Table 177. Rarecells Diagnostics. Revenue in Circulating Tumor Cell Diagnostics Business (2019-2024) & (US$ Million)

Table 178. Rarecells Diagnostics. Recent Developments

Table 179. Vitatex Inc Company Details

Table 180. Vitatex Inc Business Overview

Table 181. Vitatex Inc Circulating Tumor Cell Diagnostics Product

Table 182. Vitatex Inc Revenue in Circulating Tumor Cell Diagnostics Business (2019-2024) & (US$ Million)

Table 183. Vitatex Inc Recent Developments

Table 184. Research Programs/Design for This Report

Table 185. Key Data Information from Secondary Sources

Table 186. Key Data Information from Primary Sources

List of Figures

Figure 1. Global Circulating Tumor Cell Diagnostics Market Size Growth Rate by Type, 2019 VS 2023 VS 2030 (US$ Million)

Figure 2. Global Circulating Tumor Cell Diagnostics Market Share by Type: 2023 VS 2030

Figure 3. CTC Enrichment Features

Figure 4. CTC Detection Features

Figure 5. CTC Analysis Features

Figure 6. Global Circulating Tumor Cell Diagnostics Market Size Growth Rate by Application, 2019 VS 2023 VS 2030 (US$ Million)

Figure 7. Global Circulating Tumor Cell Diagnostics Market Share by Application: 2023 VS 2030

Figure 8. Tumorigenesis research Case Studies

Figure 9. EMT biomarkers development Case Studies

Figure 10. Cancer stem cell research Case Studies

Figure 11. Others Case Studies

Figure 12. Circulating Tumor Cell Diagnostics Report Years Considered

Figure 13. Global Circulating Tumor Cell Diagnostics Market Size (US$ Million), Year-over-Year: 2019-2030

Figure 14. Global Circulating Tumor Cell Diagnostics Market Size, (US$ Million), 2019 VS 2023 VS 2030

Figure 15. Global Circulating Tumor Cell Diagnostics Market Share by Region: 2023 VS 2030

Figure 16. Global Circulating Tumor Cell Diagnostics Market Share by Players in 2023

Figure 17. Global Top Circulating Tumor Cell Diagnostics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Circulating Tumor Cell Diagnostics as of 2023)

Figure 18. The Top 10 and 5 Players Market Share by Circulating Tumor Cell Diagnostics Revenue in 2023

Figure 19. North America Circulating Tumor Cell Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 20. North America Circulating Tumor Cell Diagnostics Market Share by Type (2019-2030)

Figure 21. North America Circulating Tumor Cell Diagnostics Market Share by Application (2019-2030)

Figure 22. North America Circulating Tumor Cell Diagnostics Market Share by Country (2019-2030)

Figure 23. United States Circulating Tumor Cell Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 24. Canada Circulating Tumor Cell Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 25. Europe Circulating Tumor Cell Diagnostics Market Size YoY (2019-2030) & (US$ Million)

Figure 26. Europe Circulating Tumor Cell Diagnostics Market Share by Type (2019-2030)

Figure 27. Europe Circulating Tumor Cell Diagnostics Market Share by Application (2019-2030)

Figure 28. Europe Circulating Tumor Cell Diagnostics Market Share by Country (2019-2030)

Figure 29. Germany Circulating Tumor Cell Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 30. France Circulating Tumor Cell Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 31. U.K. Circulating Tumor Cell Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 32. Italy Circulating Tumor Cell Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 33. Russia Circulating Tumor Cell Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 34. Nordic Countries Circulating Tumor Cell Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 35. China Circulating Tumor Cell Diagnostics Market Size YoY (2019-2030) & (US$ Million)

Figure 36. China Circulating Tumor Cell Diagnostics Market Share by Type (2019-2030)

Figure 37. China Circulating Tumor Cell Diagnostics Market Share by Application (2019-2030)

Figure 38. Asia Circulating Tumor Cell Diagnostics Market Size YoY (2019-2030) & (US$ Million)

Figure 39. Asia Circulating Tumor Cell Diagnostics Market Share by Type (2019-2030)

Figure 40. Asia Circulating Tumor Cell Diagnostics Market Share by Application (2019-2030)

Figure 41. Asia Circulating Tumor Cell Diagnostics Market Share by Region (2019-2030)

Figure 42. Japan Circulating Tumor Cell Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 43. South Korea Circulating Tumor Cell Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 44. China Taiwan Circulating Tumor Cell Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 45. Southeast Asia Circulating Tumor Cell Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 46. India Circulating Tumor Cell Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 47. Australia Circulating Tumor Cell Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 48. Middle East, Africa, and Latin America Circulating Tumor Cell Diagnostics Market Size YoY (2019-2030) & (US$ Million)

Figure 49. Middle East, Africa, and Latin America Circulating Tumor Cell Diagnostics Market Share by Type (2019-2030)

Figure 50. Middle East, Africa, and Latin America Circulating Tumor Cell Diagnostics Market Share by Application (2019-2030)

Figure 51. Middle East, Africa, and Latin America Circulating Tumor Cell Diagnostics Market Share by Country (2019-2030)

Figure 52. Brazil Circulating Tumor Cell Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 53. Mexico Circulating Tumor Cell Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 54. Turkey Circulating Tumor Cell Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 55. Saudi Arabia Circulating Tumor Cell Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 56. Israel Circulating Tumor Cell Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 57. GCC Countries Circulating Tumor Cell Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 58. Janssen Diagnostics Revenue Growth Rate in Circulating Tumor Cell Diagnostics Business (2019-2024)

Figure 59. Advanced Cell Diagnostics Revenue Growth Rate in Circulating Tumor Cell Diagnostics Business (2019-2024)

Figure 60. Aviva Biosciences Revenue Growth Rate in Circulating Tumor Cell Diagnostics Business (2019-2024)

Figure 61. Biocept Inc Revenue Growth Rate in Circulating Tumor Cell Diagnostics Business (2019-2024)

Figure 62. Biofluidica Inc. Revenue Growth Rate in Circulating Tumor Cell Diagnostics Business (2019-2024)

Figure 63. CellTraffix Inc. Revenue Growth Rate in Circulating Tumor Cell Diagnostics Business (2019-2024)

Figure 64. Clearbridge BioMedics Pte Ltd Revenue Growth Rate in Circulating Tumor Cell Diagnostics Business (2019-2024)

Figure 65. Epic Sciences Inc. Revenue Growth Rate in Circulating Tumor Cell Diagnostics Business (2019-2024)

Figure 66. Fluxion Biosciences Inc. Revenue Growth Rate in Circulating Tumor Cell Diagnostics Business (2019-2024)

Figure 67. ScreenCell Revenue Growth Rate in Circulating Tumor Cell Diagnostics Business (2019-2024)

Figure 68. Silicon Biosystems Revenue Growth Rate in Circulating Tumor Cell Diagnostics Business (2019-2024)

Figure 69. Sysmex Corporation Revenue Growth Rate in Circulating Tumor Cell Diagnostics Business (2019-2024)

Figure 70. Greiner Bio-One GmbH Revenue Growth Rate in Circulating Tumor Cell Diagnostics Business (2019-2024)

Figure 71. AdnaGen AG Revenue Growth Rate in Circulating Tumor Cell Diagnostics Business (2019-2024)

Figure 72. Apocell Inc Revenue Growth Rate in Circulating Tumor Cell Diagnostics Business (2019-2024)

Figure 73. Biocep Ltd Revenue Growth Rate in Circulating Tumor Cell Diagnostics Business (2019-2024)

Figure 74. Canopus Bioscience Ltd Revenue Growth Rate in Circulating Tumor Cell Diagnostics Business (2019-2024)

Figure 75. Creatv Microtech Inc Revenue Growth Rate in Circulating Tumor Cell Diagnostics Business (2019-2024)

Figure 76. Ikonisys Inc Revenue Growth Rate in Circulating Tumor Cell Diagnostics Business (2019-2024)

Figure 77. IV Diagnostics Inc Revenue Growth Rate in Circulating Tumor Cell Diagnostics Business (2019-2024)

Figure 78. Miltenyi Biotech GmbH Revenue Growth Rate in Circulating Tumor Cell Diagnostics Business (2019-2024)

Figure 79. Nanostring Technologies Inc Revenue Growth Rate in Circulating Tumor Cell Diagnostics Business (2019-2024)

Figure 80. Rarecells Diagnostics. Revenue Growth Rate in Circulating Tumor Cell Diagnostics Business (2019-2024)

Figure 81. Vitatex Inc Revenue Growth Rate in Circulating Tumor Cell Diagnostics Business (2019-2024)

Figure 82. Bottom-up and Top-down Approaches for This Report

Figure 83. Data Triangulation

Figure 84. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$4900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$7350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$9800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

120 Pages

Type: Report

Code: QYRE-Auto-20M14708

Sun Nov 24 00:00:00 UTC 2024

Add to Cart

Oncology Ablation Device - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

120 Pages

Type: Report

Code: QYRE-Auto-33S12918

Fri Nov 15 00:00:00 UTC 2024

Add to Cart

Interventional Oncology Ablation Device - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

120 Pages

Type: Report

Code: QYRE-Auto-9Z13187

Fri Nov 15 00:00:00 UTC 2024

Add to Cart

Invasive Fungal Infection Diagnosis - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

120 Pages

Type: Report

Code: QYRE-Auto-15A13033

Fri Nov 15 00:00:00 UTC 2024

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions

Global Circulating Tumor Cell Diagnostics Market Insights, Forecast to 2030

Published Date: September 2024

Report Code: QYRE-Othe-362

Global Circulating Tumor Cell Diagnostics Market Insights, Forecast to 2030

FEATURED COMPANIES

Circulating Tumor Cell Diagnostics Market Size

Circulating Tumor Cell Diagnostics Market

Scope of Circulating Tumor Cell Diagnostics Market Report

Chapter Outline

FAQ for this report

How fast is Circulating Tumor Cell Diagnostics Market growing?

What is the Circulating Tumor Cell Diagnostics Market size in 2030?

Who are the main players in the Circulating Tumor Cell Diagnostics Market report?

What are the Application segmentation covered in the Circulating Tumor Cell Diagnostics Market report?

What are the Type segmentation covered in the Circulating Tumor Cell Diagnostics Market report?

FEATURED COMPANIES

RELATED REPORTS